Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT00978432 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

50

Enrollment

OTHER

Sponsor class

Stopped The toxicity seemed to outweigh the benefit.

Conditions

Diffuse Large B-cell Lymphoma

Interventions

DRUG: RAD001
DRUG: LBH589
DRUG: Doublet (RAD001 and LBH589)

Sponsor

Anne Beaven, MD

Collaborators

[object Object]